The ADAPT trial, which selected baseline features of HER2-positive HR negative patients that were randomized to 12 weeks of Trastuzumab + Pertuzumab +/− weekly paclitaxel at 80 mg/m2 and had an early response (proliferation decrease ≥30% of ki67 or <500 invasive tumor cells in the 3-week biopsy). This evidence concerns the gene ERBB2 and neoplasm.